BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE
ThromboGenics NV and co-development partner BioInvent International announce today the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban, an oral anticoagulant.